Diflucan
Pfizer
Description
Diflucan contains fluconazole, a triazole antifungal agent. Its primary mode of action is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell membrane and may be responsible for the antifungal activity of fluconazole. Fluconazole has been shown to be more selective for fungal cytochrome P-450 enzymes than for various mammalian cytochrome P-450 enzyme systems
Indications
Indicated for invasive candidiasis: mucosal candidiasis including oropharyngeal, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis; chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient; vaginal candidiasis, acute or recurrent, when local therapy is not appropriate; candidal balanitis when local therapy is not appropriate; dermatomycosis including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and dermal candida infections when systemic therapy is indicated; and tinea unguinium (onychomycosis) when other agents are not considered appropriate
Price
Capsules: 50mg, £16.61; 150mg, £7.12; 200mg, £66.42; powder for oral suspension: 10mg/mL, £16.61; 200mg/5ml (35ml), £66.42
More on: Systemic antifungals